Skip to content

Developed with the lowest effective concentration of pilocarpine to minimize side effects experienced by presbyopia patients1

Help patients see the difference with Qlosi

Save today

Important Safety Information

Expand

Indication and Usage

 

Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use is a cholinergic receptor agonist indicated for the treatment of presbyopia in adults.

 

Important Safety Information

Contraindications

Hypersensitivity

 

Warnings and Precautions

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

 

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

 

Qlosi is not recommended to be used when iritis is present.

 

Qlosi should not be administered while wearing contact lenses. Remove lenses prior to the installation of Qlosi and wait 10 minutes before reinsertion.

 

Avoid touching the tip of the vial to the eye or any other surface.

 

Adverse Reactions

The most common adverse reactions (5% to 8%) are instillation site pain and headaches.

 

Please see full Prescribing Information here: qlosi.com/prescribing-information

References

  1. Holland E, Karpecki P, Fingeret M, et al. Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials. Clin Ther. 2024;46(2):104-113. doi:10.1016/ j.clinthera.2023.12.005
  2. Qlosi [package insert]. Ponte Verda, FL. Orasis Pharmaceuticals.